Gilead Sciences

First trial of Ebola antiviral begins in DRC outbreak

Researchers in the Democratic Republic of Congo began enrolling participants on July 14 in the EBO-PEP trial, the first clinical study testing Gilead Sciences' experimental antiviral obeldesivir as post-exposure prophylaxis against the Bundibugyo Ebola virus, according to ALIMA, one of…

FDA approves Trodelvy for first-line metastatic breast cancer

The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences' Trodelvy (sacituzumab govitecan-hziy) for the first-line treatment of metastatic triple-negative breast cancer, a decision that establishes the antibody-drug conjugate as a new standard of care for one of the…